Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ABUS courtesy of Howdy partners!! The markets delivered coal to traders on day 1 of December. ??
[-chart]ecp.yusercontent.com/mail?url=https%3A%2F%2Fwp.stocktwits.com%2Fwp-content%2Fuploads%2F2021%2F12%2F01180205%2Fgiphy-3.gif&t=1638409792&ymreqid=c6f2e490-95ab-649b-1c18-b3080401fb00&sig=_DqfF2Z1sQEp73K32F7PYQ--~D
Each index sold off over a percent. ?? The Russell 2K took the brunt of the selling, tumbling 2.34%. The Nasdaq shaved off 1.83% and the S&P 500 slashed 1.18%.[/chart]
[chart]ecp.yusercontent.com/mail?url=https%3A%2F%2Fwp.stocktwits.com%2Fwp-content%2Fuploads%2F2021%2F12%2F01180205%2Fgiphy-3.gif&t=1638409792&ymreqid=c6f2e490-95ab-649b-1c18-b3080401fb00&sig=_DqfF2Z1sQEp73K32F7PYQ--~D
Each index sold off over a percent. ?? The Russell 2K took the brunt of the selling, tumbling 2.34%. The Nasdaq shaved off 1.83% and the S&P 500 slashed 1.18%.[/chart]
Build-A-Bear Workshop blasted 27% to six-year highs after reporting record sales and raised guidance. Must be selling a whole lotta bears. ?? Here’s the daily chart:
Howdy partners!! The markets delivered coal to traders on day 1 of December. ??
Each index sold off over a percent. ?? The Russell 2K took the brunt of the selling, tumbling 2.34%. The Nasdaq shaved off 1.83% and the S&P 500 slashed 1.18%.
Build-A-Bear Workshop blasted 27% to six-year highs after reporting record sales and raised guidance. Must be selling a whole lotta bears. ?? Here’s the daily chart:
[-chart]ecp.yusercontent.com/mail?url=https%3A%2F%2Fwp.stocktwits.com%2Fwp-content%2Fuploads%2F2021%2F11%2F01171643%2FBBW-01_Dec_2021_15_41-600x349.png&t=1638409792&ymreqid=c6f2e490-95ab-649b-1c18-b3080401fb00&sig=MpGxG0kiZQ7prCG5IjmMNA--~D[/chart]
Square and Twitter CEO Jack Dorsey announced he was resigning as CEO of Twitter yesterday, namely because activist investors have had it out for the tech CEO since last year.
Today, Square is getting an all-new parent company: Block. Block will act as the parent that owns Square, Cash App, TIDAL, Spiral (a spinoff of Square Crypto), and TBD54566975 (a bitcoin-focused decentralized exchange.) As the name implies, each company or project is a building block part of a whole.
For anyone surprised by this move, Square’s Block pivot shares some trends among Big Tech lore. Walk with us:
1) Remember Google and Facebook? Or should we say… Alphabet and Meta? Big Tech companies love to rebrand. Dorsey reorganizing Square is tantamount to taking a pen and writing the next chapter for his payments giant. Obviously, he’s going to take Square in a new direction — one that’s all about crypto and blockchain.
2) Remember when Apple CEO Steve Jobs got thrown out of his own company in 1985? This is basically that, but even more alpha. ?? Jobs went on to found NeXT Computer out of spite. Sure, Jack probably wants to see Twitter succeed. But by all metrics, Twitter is a losing media investment whereas Square is an industry-leading payments solution.
0% of this is surprising to us. Dorsey was quoted back in June saying that Bitcoin was the most “important thing” in his lifetime to “work on.” He added that if he was not at Square or Twitter, he would be building Bitcoin. He elaborated to say both companies had a role in building the world’s largest cryptocurrency.
In our Nov. 29 edition of the Rip, we talked about how Dorsey’s move from the turbulent world of social media wouldn’t be the worst thing in the world. Instead, this pivot is an invitation for Jack to guide Square to the promised land of web3 and Bitcoin leadership. ?? ?
$SQ lost 6.6% today.
Silo Wellness (CSE: SILO) (OTCQB: SILF) (FRA: 3K70) is delivering psychedelic healing through its guided wellness retreats and the Marley One brand of natural mushroom products. This is an opportunity to be part of the next big trend, w/ a revenue generating company laying the groundwork for growth.
[-chart]ecp.yusercontent.com/mail?url=https%3A%2F%2Fwp.stocktwits.com%2Fwp-content%2Fuploads%2F2021%2F12%2F01181700%2Fgiphy-4.gif&t=1638409792&ymreqid=c6f2e490-95ab-649b-1c18-b3080401fb00&sig=jpDQn5IA7w7XbtGlLJo_VA--~D[/chart]
C3AI Inc lost 8.5% and closed at all-time lows heading into it its second-quarter earnings report. After the close, the software provider exceeded earnings and sales predictions and raised revenue guidance.
$AI | EPS: ($0.23)(vs. ($0.28) expected) | Revenue: $58.3 million (vs. $56.9 million expected) | Link to Report
https://ir.c3.ai/news/news-details/2021/C3-AI-Announces-Second-Quarter-Fiscal-2022-Results/default.aspx
[-chart]ecp.yusercontent.com/mail?url=https%3A%2F%2Fwp.stocktwits.com%2Fwp-content%2Fuploads%2F2021%2F12%2F01173824%2Fgiphy-1.gif&t=1638409792&ymreqid=c6f2e490-95ab-649b-1c18-b3080401fb00&sig=4Hmnwi3GekofXNWcVs5koQ--~D[/chart]
In the era of ESG-conscious investing (ESG stands for Environmental, Social, & Governance), we have quite the story for you. Securus Technologies, a company which operates prison phones, is in talks to go public via SPAC.
Yeah, what the… Securus Technologies could go public in a merger with Atlantic Avenue Acquisition Corp, a SPAC. The deal is controversial because Securus Technologies is a private company which profits from charging the families of incarcerated people for phone calls.
SPACs are somewhat known for challenging the ESG mission. According to Bernstein analysts, SPACs are “one of the most anti-ESG assets imaginable.” This is because SPACs acquire investors before acquiring or merging with actual companies.
Tom Gores’s Platinum Equity is a current investor in Securus Technologies. Platinum Equity is looking for ways to take Securus public — this will likely attract negative attention from social justice activists who demand the divestment of private avenues for mass incarceration.
https://www.cnbc.com/2021/12/01/a-for-profit-prison-company-is-going-public-via-spac-raising-esg-concerns-in-the-blank-check-space.html
Atlantic Avenue Acquisition Corp, according a person familiar with the matter.
In October when Digital World Acquisition Corp. announced plans to merge with former President Donald Trump’s planned social media platform, at least two hedge funds pulled out their investments after learning of the target company.
Moderna loses patent challenges. Big pharma leaders have taken enormous steps to protect their COVID vaccines from losing critical intellectual property protection.
Ironically, Moderna is being sued over its IP. Patent challenges from lesser-known biotech company, Arbutus Biopharma, might leave Moderna open to a beefier lawsuit alleging that Moderna infringed on Arbutus’ property. That could be very costly. Read more in Axios.
https://www.axios.com/moderna-covid-19-vaccine-arbutus-patents-2953dd1c-2446-4af8-9580-b387186c7ab9.html
[-chart]images.axios.com/LsSDY1nS8gfVhqDrVBbgfi06Tqw=/0x0:4700x2644/1920x1080/2021/12/01/1638383205309.jpg[/chart]
A federal appeals court on Wednesday dismissed two patent challenges from Moderna over key components involved in making its COVID-19 vaccine.
Why it matters: The court's decision to side with Arbutus Biopharma means Arbutus could potentially sue Moderna for patent infringement and demand royalties from Moderna's COVID-19 vaccine, which is expected to generate up to $18 billion of revenue this year.
Details: The patent cases have been ongoing since early 2018 and involve Arbutus' small lipid particles and other related mRNA drug technology.
In one of today's patent decisions, the court acknowledged how Shaun Ryan, Moderna's deputy general counsel, said there is "substantial risk that Arbutus may bring an infringement action relating to Moderna's COVID-19 vaccine."
Of note: Moderna doesn't specifically mention Arbutus in its quarterly and annual financial filings with the Securities and Exchange Commission.
I CAN SEE $5.00 MONDA 12-13-2021
mick went there do not see anything. can you give more specifics please. thank you and have a good night.
https://www.otcmarkets.com/stock/ABUS TO JUMP 100% ?????
Goes over $5 today
I DO NOT UNDERSTAND EITHER, WHY. SOME NO BELIEVE IN MAGIC OR DA REAL THING.
Arbutus Biopharma Corporation (ABUS)'
It’s SUPER active on Stocktwits
Why is this board so quiet?? most exciting stock on the planet right now and no one is talking.
$ABUS
Arbutus identifies molecular targets for COVID-19 treatment
December 07 2021 - 07:50AM
Seeking Alpha
Alert
Print
Share On Facebook
To read the full story on Seeking Alpha, click here.
SECRETS/HANDLING WIT WHITE GLOVE TREATMENT Arbutus Biopharma Corporation (ABUS)'
ONE MORNING PRE-MKT WE WILL SEE UPTICKS
Thanks for your input mick. Seems to me like all we need is for an analyst or two to come out and explain what would happen after some type of royaly agreement with Moderna. Then we go to the moon. Or, Moderna tries to buy ABUS outright. Why is there no talk of this??
it is my friend mmm boys shorting Arbutus Biopharma Corporation (ABUS)'
dats my price area too or much higher Arbutus Biopharma Corporation (ABUS)'
Reviewing 12-08-2021 $ABUS/ GenevantFACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
COURT DENIED $MRNA APPEAL;
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
BUY;Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment 11-19-2021
https://seekingalpha.com/article/4470947-arbutus-biopharma-recent-acquisition-of-dicerna-makes-it-an-attractive-investment
*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology.
Benzinga
also
12-01-2021
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
$ABUS
Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment
Nov. 19, 2021 7:29 PM ET
Arbutus Biopharma Corporation (ABUS)
ARWR, ASMB, DRNA,JNJ,MRNA,NONOF,NVO,VACC
40 Comments
5 Likes
Summary
Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma.
AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.
The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
Patent dispute ongoing over Moderna's Covid-19 Vaccine. Favorable ruling in favor of Arbutus from Federal Appeals Court would be huge news for the company as it relates to its patents for lipid nanoparticles.
This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »
Think about it. If moderna just buys abus for 3billion they solve all their problems and abus would be around $24 per share. How could this be trading under $4?
I can't seem to find any new info on Abus since the huge news about the patent last week. I would think this stock would be flirting with $20 on this news. Anyone know where to go for updated info/analysis of abus?
$abus new patent lnp
issued 10/21 was dated back to
2009
Sell its junk. No news for a long long time.
The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology used in the former's COVID-19 vaccine.
woke up for 4am session
SOLD 33,147 shares 5.04-5.19
mission accomplished *yawn*
#RELOADTHEDIP
ABUS insane volume on NEWS https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
loaded up expecting a run back to test 6.50 HOD
VOLUME 322,135,932 = $ 1,616,087,807 US DOLLARS
https://finviz.com/quote.ashx?t=ABUS
then short it shrek
ABUS traded more than 3 times its' OS today.
My take on the patent case, FWIW: #msg-166969942.
takes time as is is. Arbutus Biopharma Corporation (ABUS)'mgmt needs to spill some beans
what a pos
ruling means nothing
Reviewing 12-01-2021 $ABUS FACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
COURT DENIED $MRNA APPEAL;
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology.
Benzinga
also
12-01-2021
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (cHBV) infection and to treat coronaviruses (including COVID-19), today announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, AB-836, is generally safe and well-tolerated in both healthy subjects and patients with cHBV and provides robust antiviral activity.
Gaston Picchio, Ph.D., Chief Development Officer at Arbutus, commented, “These preliminary results demonstrate that AB-836 is generally safe and well-tolerated in both single- and multiple-doses in healthy subjects and at doses up to 100mg administered once daily for 28 days in cHBV patients. In addition, the mean Day 28 drop in HBV DNA observed to date with a relatively low dose suggests that AB-836 is a very potent inhibitor of HBV replication making it an ideal candidate to potentially completely suppress viral replication. We look forward to continuing to evaluate the safety and efficacy of AB-836 in Part 3 of this trial.”
The Phase 1a/1b clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple doses of AB-836 in healthy subjects and patients with cHBV. The trial consists of three parts. Part 1 evaluated alternating single doses of AB-836 or placebo ranging from 10mg to 175mg in a fasted or fed state in healthy subjects. Part 2 evaluated multiple ascending doses of 50mg, 100mg or 150mg of AB-836 or placebo once daily for 10 days in healthy volunteers. Part 3, which is still on-going, is currently randomizing HBV DNA positive cHBV patients who are HBeAg positive or negative to receive either 50mg or 100mg of AB-836 or placebo once daily for 28 days.
In Parts 1 and 2, a total of 47 healthy subjects were enrolled and dosed. There were no deaths or serious adverse events (SAEs) observed. One healthy subject that received 50mg once daily discontinued after treatment on day 13 due to an adverse event (AE) of agitation. All but three AEs were mild (Grade 2 headache, agitation and bronchitis), and only one was assessed as related to AB-836 (Grade 1 rash). There were no clinically significant abnormalities in clinical laboratory tests, ECGs, vital signs or physical exams noted.
In Part 3, 16 cHBV patients have been dosed thus far with enrollment continuing. Among those who received 100mg once daily for the full 28 days (n=4), robust antiviral activity was observed at Day 28 of treatment with a mean (SE) log10 change from baseline of -3.1 (0.5). There have been no deaths or AEs. One cHBV patient that received 100mg of AB-836 had a transient increase in ALT from baseline Grade 1 to Grade 3 at a single visit that resolved with continued dosing and had no associated symptoms. There were no clinically significant abnormalities in ECGs, vital signs or physical exams noted.
Arbutus is continuing to enroll and dose cHBV patients in Part 3 of the clinical trial and anticipates presenting additional data at a medical conference in 2022.
About AB-836
AB-836 is a next generation oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. The current standard-of-care therapy for HBV is primarily nucleos(t)ide analogues that inhibit the viral polymerase and significantly reduce, but do not eliminate viral replication. AB-836 in combination with nucleos(t)ide analogues is designed to completely eliminate viral replication in infected cells by preventing the assembly of functional viral capsids. In addition, AB-836 has been shown to inhibit the replenishment of covalently closed circular DNA (cccDNA), the viral genetic reservoir which the virus needs to replicate itself.
About HBV
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that suppress viral replication, reduce surface antigen and reawaken the immune system. Arbutus believes this three-prong approach is key to transforming the treatment and developing a potential cure for chronic HBV infection. Arbutus’ HBV product pipeline includes RNA interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit PD-L1 and oral HBV RNA destabilizers. In addition, Arbutus has an ongoing drug discovery and development program directed to identifying orally active agents for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about our future development plans for our product candidates; the expected cost, timing and results of our clinical development plans and clinical trials with respect to our product candidates; our expectations and goals for our collaborations with third parties and any potential benefits related thereto; and the potential for our product candidates to achieve success in clinical trials.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic.
Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; Arbutus and its collaborators may never realize the expected benefits of the collaborations; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Primary Logo
Healthcare & Pharmaceuticals
Moderna could be sued over vaccines as court upholds patents
By Brendan Pierson
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
Dec 1 (Reuters) - Moderna Inc (MRNA.O) could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp (ABUS.O).
The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents, which may cover technology used in the vaccines, are not obvious in light of previously known science and so are valid.
Arbutus shares were up $1.63, or 51% higher, at $4.83. Moderna shares fell almost 9% to $321.15.
Moderna and Arbutus did not immediately respond to requests for comment.
Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents are upheld.
The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.
Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.
Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.
ONLY 10 MESSAGES WIT NEWS LIKE AH DIS ????? WOW $ABUS
AND PATENT GOT ANOTHER UPDATE FROM F.D.A. APPROVAL RECENTLY. $ABUS
I WAS RIIGHT, $ABUS BEEN SAYING $ABUS
PATENT INFRINGEMENT
12-01-2021
COURT RELEASE $MRNA APPEAL DENIED.
FOOD FER THOUGHT
OTHERS PHARMA INVOLVED TOO.
I HOPE SOME GOT SOME $3'S PLUS LAST WK.
I THINK EARLY MORNING YESTERDAY WAS HIGH 3'S
GL TO ALL.
powerful tweet
WOW RIPPING NHOD!!!
ABUS
I JOINED LATE 4.70'S
The double win on the patent is sweet.
I was waiting for it to get to $2.50 so I could double down. Darn.
See any reason for it, aries?
I see ROIV is up, too.
Its about time these courts work way too slow
Nov 10th Corporate Presentation: https://investor.arbutusbio.com/static-files/71304c69-6d46-4a8c-b5f3-6f16bc4a7028
Interesting read on Moderna.
BTW, got your message. Can't reply until Happy Hour on Friday since I don't have paid subscription, but I'll try to reply privately on Friday or I'll post publicly on message board where you found me.
Bigger patent problems for Moderna that just ABUS!
https://www.nytimes.com/2021/11/09/us/moderna-vaccine-patent.html
WASHINGTON — Moderna and the National Institutes of Health are in a bitter dispute over who deserves credit for inventing the central component of the company’s powerful coronavirus vaccine, a conflict that has broad implications for the vaccine’s long-term distribution and billions of dollars in future profits.
The vaccine grew out of a four-year collaboration between Moderna and the N.I.H., the government’s biomedical research agency — a partnership that was widely hailed when the shot was found to be highly effective. A year ago this month, the government called it the “N.I.H.-Moderna Covid-19 vaccine.”
what ah dog Arbutus Biopharma Co (ABUS)
3.45 ? -0.43 (-11.08%)
Volume: 3,655,371 @11/05/21 7:58:36 PM EDT
Bid Ask Day's Range
3.45 50.0 3.4 - 3.7
ABUS Detailed Quote
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |